TF
CPRX

Tompkins Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Tompkins Financial’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$13 – 592
2023
Q2 		$13 Hold
1
– – ﹤0.01% 604
2023
Q1 		$17 Buy
+1
New +$16 ﹤0.01% 631

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tompkins Financial's CPRX Position: Q3 2023 in Review

Tompkins Financial sold out of Catalyst Pharmaceutical (CPRX) in Q3 2023, closing a stake of 1 share — an estimated $13 sold.

Tompkins Financial first reported a position in CPRX in Q1 2023 and held it in 2 quarters. The position peaked at $17 in Q1 2023. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

  • Tompkins Financial reported no remaining Catalyst Pharmaceutical position as of Q3 2023 after selling out during the quarter.
  • Tompkins Financial sold 1 Catalyst Pharmaceutical share in Q3 2023, an estimated $13.
  • Tompkins Financial first reported a position in Catalyst Pharmaceutical in Q1 2023 and held it in 2 quarters.
  • Tompkins Financial's Catalyst Pharmaceutical position peaked at $17 in Q1 2023.
  • 255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on Tompkins Financial's 13F filing for Q3 2023, filed 21 Nov 2023.